Considering the Treatment of IgA Nephropathy.
作者信息
Lafayette Richard A, Kamal Fahmeedah S
机构信息
Division of Nephrology , Stanford University Medical Center , Stanford , California.
出版信息
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1113-1115. doi: 10.2215/CJN.0000000000000261. Epub 2023 Aug 3.
Abstract
摘要
相似文献
1
Considering the Treatment of IgA Nephropathy.关于IgA肾病的治疗
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1113-1115. doi: 10.2215/CJN.0000000000000261. Epub 2023 Aug 3.
2
A case of de novo glomerulonephritis following COVID-19 in a patient with preexistent IgA vasculitis.一名患有既往IgA血管炎的患者在感染COVID-19后发生新发肾小球肾炎的病例。
CEN Case Rep. 2025 Apr;14(2):236-241. doi: 10.1007/s13730-024-00940-9. Epub 2024 Oct 13.
3
Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.霉酚酸酯治疗IgA肾病的疗效与安全性：一项系统评价
BMC Nephrol. 2014 Dec 5;15:193. doi: 10.1186/1471-2369-15-193.
4
Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.钙调磷酸酶抑制剂联合激素治疗 IgA 肾病的潜在获益及相关作用：系统评价和荟萃分析。
Int Urol Nephrol. 2023 Sep;55(9):2227-2236. doi: 10.1007/s11255-023-03524-1. Epub 2023 Mar 1.
5
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy.Zigakibart在健康志愿者和IgA肾病患者的1/2期试验中显示出临床安全性和有效性。
Kidney Int. 2025 Jun 5. doi: 10.1016/j.kint.2025.05.006.
6
Successful treatment of MPO-ANCA positive crescentic IgA nephropathy/IgA vasculitis with nephritis potentially triggered by a COVID-19 vaccine in a young adult female using corticosteroids, rituximab, and avacopan.在一名年轻成年女性中，使用皮质类固醇、利妥昔单抗和阿伐可泮成功治疗了可能由新冠疫苗引发的MPO-ANCA阳性新月体性IgA肾病/IgA血管炎伴肾炎。
CEN Case Rep. 2025 Apr 9. doi: 10.1007/s13730-025-00991-6.
7
Selecting Treatment for IgA Nephropathy.IgA肾病的治疗选择
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1109-1110. doi: 10.2215/CJN.0000000000000263. Epub 2023 Aug 9.
8
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.羟氯喹对 IgA 肾病蛋白尿的影响：系统评价和荟萃分析。
Biomed Res Int. 2021 Dec 3;2021:9171715. doi: 10.1155/2021/9171715. eCollection 2021.
9
An adolescent presenting with IgA nephropathy and persistent decreased kidney function after COVID-19 vaccination during follow-up for asymptomatic hematuria: a clinicopathological study.一名青少年在无症状血尿随访期间接种新冠病毒疫苗后出现IgA肾病且肾功能持续下降：一项临床病理研究
CEN Case Rep. 2025 Apr 13. doi: 10.1007/s13730-025-00989-0.
10
Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report.泰吉华单抗治疗IgA血管炎肾病的疗效：两例报告
Front Immunol. 2025 May 1;16:1564242. doi: 10.3389/fimmu.2025.1564242. eCollection 2025.
本文引用的文献
1
Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting.在真实世界环境中，IgA 肾病的肾脏结局比较：免疫抑制与支持治疗。
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1186-1194. doi: 10.2215/CJN.0000000000000215. Epub 2023 Jun 14.
2
Long-Term Outcomes in IgA Nephropathy.IgA 肾病的长期预后。
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13.
3
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.斯巴森坦治疗 IgA 肾病患者：一项随机、双盲、活性对照临床试验的预先指定中期分析。
Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.
4
Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.霉酚酸酯在进行性IgA肾病患者中的疗效：一项随机临床试验。
JAMA Netw Open. 2023 Feb 1;6(2):e2254054. doi: 10.1001/jamanetworkopen.2022.54054.
5
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.多中心、双盲、随机、安慰剂对照的 NefIgArd 试验 A 部分的结果，该试验评估了布地奈德靶向释放制剂治疗原发性免疫球蛋白 A 肾病。
Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19.
6
The epidemiology and evolution of IgA nephropathy over two decades: A single centre experience.二十年来 IgA 肾病的流行病学和演变：单中心经验。
PLoS One. 2022 Sep 1;17(9):e0268421. doi: 10.1371/journal.pone.0268421. eCollection 2022.
7
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.口服甲泼尼龙对 IgA 肾病患者肾功能下降或肾衰竭的影响：TESTING 随机临床试验。
JAMA. 2022 May 17;327(19):1888-1898. doi: 10.1001/jama.2022.5368.
8
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.应用国际 IgA 肾病预测工具于活检后一至两年。
Kidney Int. 2022 Jul;102(1):160-172. doi: 10.1016/j.kint.2022.02.042. Epub 2022 Apr 29.
9
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
10
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.预先设定的 DAPA-CKD 试验分析表明，达格列净可改善 IgA 肾病患者的主要不良肾脏事件。
Kidney Int. 2021 Jul;100(1):215-224. doi: 10.1016/j.kint.2021.03.033. Epub 2021 Apr 18.
Zotero 插件